广药集团拟投100亿至150亿创新转型

Core Viewpoint - During the 15th Five-Year Plan period, Guangzhou Pharmaceutical Group plans to invest approximately 10 billion to 15 billion yuan in R&D and allocate about 20 billion to 30 billion yuan for industrial investment and mergers and acquisitions to promote innovation and transformation [1] Group 1: Strategic Collaborations - Guangzhou Pharmaceutical Group has established a strategic partnership with Muen Bio to advance the industrial application of microbiological technologies [1] - Collaborations have been initiated with Digital Science Group and Huawei Technologies to enhance the information management level of drug safety through the "Drug Vigilance Intelligent Management System" project [1] - Partnerships have been formed with Central South University, Capton Company, and others to promote collaborative efforts in production, education, and research [1] Group 2: New Business Directions - Collaborations with the Guangzhou Development Zone Management Committee and various hospitals aim to advance the full industrial chain development of nuclear medicine [1] - Guangzhou Animal Health Technology Company has signed agreements with various pet hospital management companies to expand into the animal health business [1] - The Fruit Tree Science Research Institute has signed a cooperation agreement with Zhanjiang Agricultural Reclamation Science Research Institute to conduct trials on new variety facility cultivation [1] Group 3: Capital Operations - Guangzhou Capital is engaging in partnerships with multiple companies to accelerate capital operations and expand its industrial footprint [1]